Cellumen, Inc.
Cellumen is the Systems Cell Biology company that is focused on delivering cellular models of disease and cytotoxicity that will revolutionize the drug discovery process and improve the quality of compounds entering clinical trials. The same systems cell biology approach is also being developed to optimize personalized medicine for clinical trials.
www.cellumen.com
|
Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases such as Alzheimer’s. Cognition’s approach combines biological expertise around protein targets, proprietary assays that emphasize functional responses, and proprietary chemistry that insures novel, high quality small-molecule drug candidates.
www.CogRx.com
|
Crystalplex Corporation
Crystalplex develops and commercializes innovative fluorescent markers for use in biological research and testing. Our technology is based on our proprietary composition-tunable nanocrystals (quantum dots). Our PLxBeadTM products enable researchers to collect multiple results simultaneously from very small sample volumes. PLxBeadsTM provide an easy-to-use solution to the cumbersome methods currently used to derive protein and genetic information. Crystalplex products promise to reduce the labor and shorten the time required for academic and pharmaceutical research.
www.crystalplex.com
|
Diamyd, Inc. (formerly Nurel Therapeutics)
Diamyd, Inc. was formed through the acquisition of Nurel Therapeutics in December 2005 and is the wholly-owned US subsidiary of Diamyd Medical AB, a publicly traded company based in Stockholm, Sweden. Diamyd Medical's lead product, Diamyd®, is a novel protein therapy for the prevention of the onset of diabetes and is currently in two Phase 2 clinical trials in Sweden. At its Pittsburgh location, Diamyd is developing novel products for the treatment of diabetes and its complications including chronic pain and diabetic neuropathy. Diamyd's proprietary nerve targeting delivery system was developed at the University of Pittsburgh and has numerous additional applications including potential therapies for the treatment of cancer and central nervous systems disorders.
www.diamyd.com
|
Fluorous Technologies, Inc.
Fluorous Technologies, Inc. (FTI) manufactures a variety of products that facilitate the use of fluorous chemistry in traditional and high-throughput synthesis. These products are marketed under the trade name FluoroFlash®, and include fluorous protecting groups, fluorous reagents for specific synthetic reactions, fluorous scavengers, fluorous building blocks, and fluorous sorbents in a variety of formats.
www.fluorous.com
|